Humacyte rises after positive data from humanitarian study of Symvess
Source: SeekingAlpha
2025-10-06 16:09:46 ET
More on Humacyte
- Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress
- Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
- Humacyte, Senseonics jump as Barclays issues new Overweight ratings
- Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
- Seeking Alpha’s Quant Rating on Humacyte
Read the full article on Seeking Alpha
For further details see:
Humacyte rises after positive data from humanitarian study of Symvess
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
-3.85% G/L:
$1.14 Last:
1,388,921 Volume:
$1.19 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
